Left Atrial Appendage Closure With the LAmbre

Completed

Trial Description

The study was to retrospectively analyse the efficacy and safety of LAA closure using the LAmbre in our center from April 2014 to November 2015.

Detailed Description

The study was to retrospectively analyse the efficacy and safety of percutaneous left atrial appendage (LAA) closure using the LAmbre (Lifetech Scientific Co., Ltd., Shenzhen, China) in our center from April 2014 to November 2015. 89.4% has finished the 12-month esophageal ecllocardiogrhy (TEE) examination. The average followup was 2-years.

Conditions

Interventions

Percutaneous Left Atrial Appendage Closure Using the LAmbre Device in Patients With Atrial Fibrillation

ARM 1:

Kind: Experimental

Label: LAA closure with LAmbre

Description: The patients with atrial fibrillation who received left atrial appendage (LAA) closure using the LAmbre device in our center from April 2014 to November 2015.

Trial Population

The aim of this retrospective study was to evaluate the long-term follow-up results
associated with left atrial appendage closure (LAAC) with the LAmbre (Lifetech Scientific
Corp., Shenzhen, China) in patients with nonvalvular atrial fibrillation (NVAF).

Professionals

Education

We comply with the "Health on the Net" (HON) code of standards for trustworthy health information: verify here.

This project is supported in part by the NIH Specialized Programs of Translational Research in Acute Stroke (SPOTRIAS) Network, and NINDS grant 3P50NS055977 to Washington University in St. Louis School of Medicine and UT Southwestern Medical Center.